Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity

References

• Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol: official journal of the American Society of Clinical Oncology. 2015;33(17):1974–82. doi:10.1200/JCO.2014.59.4358. PMID:25605845.
   PubMed Web of Science ®Google Scholar
• Pitt JM, Vetizou M, Daillere R, Roberti MP, Yamazaki T, Routy B, Lepage P, Boneca IG, Chamaillard M, Kroemer G, et al. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. Immunity. 2016;44(6):1255–69. doi:10.1016/j.immuni.2016.06.001. PMID:27332730.
   PubMed Web of Science ®Google Scholar
• Thomas HE, Mercer CA, Carnevalli LS, Park J, Andersen JB, Conner EA, Tanaka K, Matsutani T, Iwanami A, Aronow BJ, et al. mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma. Sci Transl Med. 2012;4(139):139ra84. doi:10.1126/scitranslmed.3003923. PMID:22539746.
   PubMed Web of Science ®Google Scholar
• Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, Godwin AK, Testa JR. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene. 2004;23(34):5853–7. doi:10.1038/sj.onc.1207721. PMID:15208673.
   PubMed Web of Science ®Google Scholar
• Ezell SA, Wang S, Bihani T, Lai Z, Grosskurth SE, Tepsuporn S, Davies BR, Huszar D, Byth KF. Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma. Oncotarget. 2016;7(8):9163–74. doi:10.18632/oncotarget.7036. PMID:26824321.
   PubMedGoogle Scholar
• Guichard SM, Curwen J, Bihani T, D'Cruz CM, Yates JW, Grondine M, Howard Z, Davies BR, Bigley G, Klinowska T. AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules. Mol Cancer Ther. 2015;14(11):2508–18. doi:10.1158/1535-7163.MCT-15-0365. PMID:26358751.
   PubMed Web of Science ®Google Scholar
• Dumont FJ, Staruch MJ, Koprak SL, Melino MR, Sigal NH. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J. Immunol. 1990;144(1):251–8.
   PubMed Web of Science ®Google Scholar
• Kreis H, Cisterne JM, Land W, Wramner L, Squifflet JP, Abramowicz D, Morales JM, Grinyo JM, Mourad G, Berthoux FC, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation. 2000;69(7):1252–60. doi:10.1097/00007890-200004150-00009. PMID:10798738.
   PubMed Web of Science ®Google Scholar
• Powell JD, Pollizzi KN, Heikamp EB, Horton MR. Regulation of immune responses by mTOR. Annu Rev Immunol. 2012;30:39–68. doi:10.1146/annurev-immunol-020711-075024. PMID:22136167.
   PubMed Web of Science ®Google Scholar
• Sukhbaatar N, Hengstschlager M, Weichhart T. mTOR-Mediated Regulation of Dendritic Cell Differentiation and Function. Trends in immunology. 2016;37(11):778–89. doi:10.1016/j.it.2016.08.009. PMID:27614799.
   PubMed Web of Science ®Google Scholar
• Chaoul N, Fayolle C, Desrues B, Oberkampf M, Tang A, Ladant D, Leclerc C. Rapamycin Impairs Antitumor CD8+ T-cell Responses and Vaccine-Induced Tumor Eradication. Cancer Res. 2015;75(16):3279–91. doi:10.1158/0008-5472.CAN-15-0454. PMID:26122844.
   PubMed Web of Science ®Google Scholar
• Moore EC, Cash HA, Caruso AM, Uppaluri R, Hodge JW, Van Waes C, Allen CT. Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers. Cancer Immunol Res. 2016;4(7):611–20. doi:10.1158/2326-6066.CIR-15-0252. PMID:27076449.
   PubMed Web of Science ®Google Scholar
• Pollizzi KN, Patel CH, Sun IH, Oh MH, Waickman AT, Wen J, Delgoffe GM, Powell JD. mTORC1 and mTORC2 selectively regulate CD8(+) T cell differentiation. J Clin Invest. 2015;125(5):2090–108. doi:10.1172/JCI77746. PMID:25893604.
   PubMed Web of Science ®Google Scholar
• Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM, Gray NS. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem. 2009;284(12):8023–32. doi:10.1074/jbc.M900301200. PMID:19150980.
   PubMed Web of Science ®Google Scholar
• Liu Q, Kirubakaran S, Hur W, Niepel M, Westover K, Thoreen CC, Wang J, Ni J, Patricelli MP, Vogel K, et al. Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics. J Biol Chem. 2012;287(13):9742–52. doi:10.1074/jbc.M111.304485. PMID:22223645.
   PubMed Web of Science ®Google Scholar
• Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci U S A. 2008;105(45):17414–9. doi:10.1073/pnas.0809136105. PMID:18955708.
   PubMed Web of Science ®Google Scholar
• Mosely SI, Prime JE, Sainson RC, Koopmann JO, Wang DY, Greenawalt DM, Ahdesmaki MJ, Leyland R, Mullins S, Pacelli L, et al. Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery. Cancer Immunol Res. 2017;5(1):29–41. doi:10.1158/2326-6066.CIR-16-0114. PMID:27923825.
   PubMed Web of Science ®Google Scholar
• Zhang B, Halder SK, Zhang S, Datta PK. Targeting transforming growth factor-beta signaling in liver metastasis of colon cancer. Cancer letters. 2009;277(1):114–20. doi:10.1016/j.canlet.2008.11.035. PMID:19147275.
   PubMed Web of Science ®Google Scholar
• Ihle NT, Lemos R, Jr., Wipf P, Yacoub A, Mitchell C, Siwak D, Mills GB, Dent P, Kirkpatrick DL, Powis G, et al. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res. 2009;69(1):143–50. doi:10.1158/0008-5472.CAN-07-6656. PMID:19117997.
   PubMed Web of Science ®Google Scholar
• Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, Russo M, Cancelliere C, Zecchin D, Mazzucchelli L, et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest. 2010;120(8):2858–66. doi:10.1172/JCI37539. PMID:20664172.
   PubMed Web of Science ®Google Scholar
• Amir E, Freedman O, Carlsson L, Dranitsaris G, Tomlinson G, Laupacis A, Tannock IF, Clemons M. Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer. Am J Clin Oncol. 2013;36(5):436–42. doi:10.1097/COC.0b013e3182568f7a. PMID:22781385.
   PubMed Web of Science ®Google Scholar
• Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAS, Andrews MC, Sharma P, Wang J, Wargo JA, Pe'er D, et al. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell. 2017;170(6):1120−33 e17. doi:10.1016/j.cell.2017.07.024.
   Web of Science ®Google Scholar
• Ikeda H, Old LJ, Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine & growth factor reviews. 2002;13(2):95–109. doi:10.1016/S1359-6101(01)00038-7.
   PubMed Web of Science ®Google Scholar
• Fu T, He Q, Sharma P. The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. Cancer Res. 2011;71(16):5445–54. doi:10.1158/0008-5472.CAN-11-1138. PMID:21708958.
   PubMed Web of Science ®Google Scholar
• Amiel E, Everts B, Freitas TC, King IL, Curtis JD, Pearce EL, Pearce EJ. Inhibition of mechanistic target of rapamycin promotes dendritic cell activation and enhances therapeutic autologous vaccination in mice. J Immunol. 2012;189(5):2151–8. doi:10.4049/jimmunol.1103741. PMID:22826320.
   PubMed Web of Science ®Google Scholar
• Ohtani M, Nagai S, Kondo S, Mizuno S, Nakamura K, Tanabe M, Takeuchi T, Matsuda S, Koyasu S. Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells. Blood. 2008;112(3):635–43. doi:10.1182/blood-2008-02-137430. PMID:18492954.
   PubMed Web of Science ®Google Scholar
• Raich-Regue D, Fabian KP, Watson AR, Fecek RJ, Storkus WJ, Thomson AW. Intratumoral delivery of mTORC2-deficient dendritic cells inhibits B16 melanoma growth by promoting CD8(+) effector T cell responses. Oncoimmunology. 2016;5(6):e1146841. doi:10.1080/2162402X.2016.1146841. PMID:27471613.
   PubMed Web of Science ®Google Scholar
• Sinclair C, Bommakanti G, Gardinassi L, Loebbermann J, Johnson MJ, Hakimpour P, Hagan T, Benitez L, Todor A, Machiah D, et al. mTOR regulates metabolic adaptation of APCs in the lung and controls the outcome of allergic inflammation. Science. 2017;357(6355):1014–21. doi:10.1126/science.aaj2155. PMID:28798047.
   PubMed Web of Science ®Google Scholar
• Weichhart T, Costantino G, Poglitsch M, Rosner M, Zeyda M, Stuhlmeier KM, Kolbe T, Stulnig TM, Hörl WH, Hengstschläger M, et al. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity. 2008;29(4):565–77. doi:10.1016/j.immuni.2008.08.012. PMID:18848473.
   PubMed Web of Science ®Google Scholar
• Carrabba MG, Castelli C, Maeurer MJ, Squarcina P, Cova A, Pilla L, Renkvist N, Parmiani G, Rivoltini L. Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues. Cancer Res. 2003;63(7):1560–7. PMID:12670905.
   PubMed Web of Science ®Google Scholar
• Auphan-Anezin N, Verdeil G, Schmitt-Verhulst AM. Distinct thresholds for CD8 T cell activation lead to functional heterogeneity: CD8 T cell priming can occur independently of cell division. J Immunol. 2003;170(5):2442–8. doi:10.4049/jimmunol.170.5.2442.
   PubMed Web of Science ®Google Scholar
• Boyman O, Cho JH, Sprent J. The role of interleukin-2 in memory CD8 cell differentiation. Adv Exp Med Biol. 2010;684:28–41. doi:10.1007/978-1-4419-6451-9_3. PMID:20795538.
   PubMed Web of Science ®Google Scholar
• Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012;12(3):180–90. doi:10.1038/nri3156. PMID:22343569.
   PubMed Web of Science ®Google Scholar
• Smith K, Seddon B, Purbhoo MA, Zamoyska R, Fisher AG, Merkenschlager M. Sensory adaptation in naive peripheral CD4 T cells. J Exp Med. 2001;194(9):1253–61. doi:10.1084/jem.194.9.1253. PMID:11696591.
   PubMed Web of Science ®Google Scholar
• Saini M, Sinclair C, Marshall D, Tolaini M, Sakaguchi S, Seddon B. Regulation of Zap70 expression during thymocyte development enables temporal separation of CD4 and CD8 repertoire selection at different signaling thresholds. Science signaling. 2010;3(114):ra23. doi:10.1126/scisignal.2000702. PMID:20332428.
   PubMed Web of Science ®Google Scholar
• Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, Larsen CP, Ahmed R. mTOR regulates memory CD8 T-cell differentiation. Nature. 2009;460(7251):108–12. doi:10.1038/nature08155. PMID:19543266.
   PubMed Web of Science ®Google Scholar
• Sinclair C, Bains I, Yates AJ, Seddon B. Asymmetric thymocyte death underlies the CD4:CD8 T-cell ratio in the adaptive immune system. Proc Natl Acad Sci U S A. 2013;110(31):E2905−14. doi:10.1073/pnas.1304859110. PMID:23858460.
   PubMed Web of Science ®Google Scholar
• Pearson C, Silva A, Saini M, Seddon B. IL-7 determines the homeostatic fitness of T cells by distinct mechanisms at different signalling thresholds in vivo. Eur J Immunol. 2011;41(12):3656–66. doi:10.1002/eji.201141514. PMID:21932447.
   PubMed Web of Science ®Google Scholar
• Lode HN, Xiang R, Duncan SR, Theofilopoulos AN, Gillies SD, Reisfeld RA. Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12. Proc Natl Acad Sci U S A. 1999;96(15):8591–6. doi:10.1073/pnas.96.15.8591. PMID:10411920.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014;192(12):5451–8. doi:10.4049/jimmunol.1490019.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang XY, Subjeck JR, Shrikant PA, Kim HL. Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines. Br J Cancer. 2011;104(4):643–52. doi:10.1038/bjc.2011.15. PMID:21285988.
   PubMed Web of Science ®Google Scholar
• Pedicord VA, Cross JR, Montalvo-Ortiz W, Miller ML, Allison JP. Friends not foes: CTLA-4 blockade and mTOR inhibition cooperate during CD8+ T cell priming to promote memory formation and metabolic readiness. J Immunol. 2015;194(5):2089–98. doi:10.4049/jimmunol.1402390.
   PubMed Web of Science ®Google Scholar
• Ezell SA, Mayo M, Bihani T, Tepsuporn S, Wang S, Passino M, Grosskurth SE, Collins M, Parmentier J, Reimer C, et al. Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma. Oncotarget. 2014;5(13):4990–5001. doi:10.18632/oncotarget.2071.
   PubMed Web of Science ®Google Scholar
• Ruffell B, Chang-Strachan D, Chan V, Rosenbusch A, Ho CM, Pryer N, Daniel D, Hwang ES, Rugo HS, Coussens LM. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer cell. 2014;26(5):623–37. doi:10.1016/j.ccell.2014.09.006. PMID:25446896.
   PubMed Web of Science ®Google Scholar
• Jacobs N, Giannini SL, Doyen J, Baptista A, Moutschen M, Boniver J, Delvenne P. Inverse modulation of IL-10 and IL-12 in the blood of women with preneoplastic lesions of the uterine cervix. Clin Exp Immunol. 1998;111(1):219–24. doi:10.1046/j.1365-2249.1998.00437.x. PMID:9472685.
   PubMed Web of Science ®Google Scholar
• Knutson KL, Disis ML. IL-12 enhances the generation of tumour antigen-specific Th1 CD4 T cells during ex vivo expansion. Clin Exp Immunol. 2004;135(2):322–9. doi:10.1111/j.1365-2249.2004.02360.x. PMID:14738463.
   PubMed Web of Science ®Google Scholar
• Grayson JM, Zajac AJ, Altman JD, Ahmed R. Cutting edge: increased expression of Bcl-2 in antigen-specific memory CD8+ T cells. J Immunol. 2000;164(8):3950–4. doi:10.4049/jimmunol.164.8.3950.
   PubMed Web of Science ®Google Scholar
• Mannick JB, Del Giudice G, Lattanzi M, Valiante NM, Praestgaard J, Huang B, Lonetto MA, Maecker HT, Kovarik J, Carson S, et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med. 2014;6(268):268ra179. doi:10.1126/scitranslmed.3009892. PMID:25540326.
   PubMed Web of Science ®Google Scholar
• Johnson SC, Rabinovitch PS, Kaeberlein M. mTOR is a key modulator of ageing and age-related disease. Nature. 2013;493(7432):338–45. doi:10.1038/nature11861. PMID:23325216.
   PubMed Web of Science ®Google Scholar
• Jung CH, Ro SH, Cao J, Otto NM, Kim DH. mTOR regulation of autophagy. FEBS letters. 2010;584(7):1287–95. doi:10.1016/j.febslet.2010.01.017. PMID:20083114.
   PubMed Web of Science ®Google Scholar
• Xu X, Araki K, Li S, Han JH, Ye L, Tan WG, Konieczny BT, Bruinsma MW, Martinez J, Pearce EL, et al. Autophagy is essential for effector CD8(+) T cell survival and memory formation. Nat immunol. 2014;15(12):1152–61. doi:10.1038/ni.3025. PMID:25362489.
   PubMed Web of Science ®Google Scholar
• Gotwals P, Cameron S, Cipolletta D, Cremasco V, Crystal A, Hewes B, Mueller B, Quaratino S, Sabatos-Peyton C, Petruzzelli L, et al. Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat Rev Cancer. 2017;17(5):286–301. doi:10.1038/nrc.2017.17. PMID:28338065.
   PubMed Web of Science ®Google Scholar
• Zeng, H. mTOR signaling in immune cells and its implications for cancer immunotherapy. Cancer letters. 2017;408:182–189.
   Google Scholar
• Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clinical pharmacokinetics. 2004;43(2):83–95. doi:10.2165/00003088-200443020-00002. PMID:14748618.
   PubMed Web of Science ®Google Scholar
• Lyons AB, Parish CR. Determination of lymphocyte division by flow cytometry. J Immunol Methods. 1994;171(1):131–7. doi:10.1016/0022-1759(94)90236-4. PMID:8176234.
   PubMed Web of Science ®Google Scholar
• Lyons AB. Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J Immunol Methods. 2000;243(1-2):147–54. doi:10.1016/S0022-1759(00)00231-3. PMID:10986412.
   PubMed Web of Science ®Google Scholar